FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> swine flu | Sinovac Biotech | Novartis

Baxter, Sinovac racing through swine flu vax trials

Tools

With a full-scale pandemic alert lifting share prices at the world's leading vaccine companies, researchers are leaping into experimental trials with an eye to taking the lead in the frenzied race to produce the world's first approved swine flu vaccine.

China's Sinovac Biotech says it can complete a clinical trial by the end of July. Baxter International, meanwhile, says it thinks it can start filling orders next month. And Novartis says it believes it can have a vaccine ready for sale in the autumn. The Financial Times is reporting today that Novartis won't give the vaccine to developing countries for free, but is considering discounts.

"The most difficult part is that we are not sure about the performance of the virus seed since it is completely new to us," Sinovac's regulatory director, Gong Xuejie, told Reuters. "Time is very short. We don't know whether we will be able to produce enough vaccines before the second wave of mass breakout."

While swine flu has proven to be relatively mild as it spreads around the globe, each new death triggers fresh headlines and raises the prospect of an ambitious vaccination program around the world.

- read the report from Reuters
- here's the Financial Times article

Related Articles:
Novartis takes lead position in frenzied race for new flu vax
Four big vax makers charge ahead with swine flu programs
Billions budgeted for swine flu as programs launch
Vax makers in global race to create swine flu jab

Bookmark and Share
Get Your FREE FierceBiotech Email Newsletter:
Comments (1) | Post a comment
More stories about swine flu   Sinovac Biotech   Novartis  

Comments

I am skeptical of the record setting time line of development for the Baxter AH1N1 vaccine.

This company is coming out with a sellable product weeks ahead of what has been previously thought to be possible for bio science to produce. The suspicion of AH1N1 being a lab created virus should be thoroughly investigated.

It just would not do, to allow Baxter to benefit from a virus that THEY COULD BE HELD RESPONSIBLE FOR RELEASING IN THE FIRST PLACE.

Baxter has a history of doing just that.

Earlier this year, Baxter mixed live H5N1 virus with H3N2 seasonal flu vaccine in America, shipped it to 5 different labs in 4 different European countries, where it was transformed into hundreds of thousands of nasal applicator doses, that were then shipped to 18 different countries before the "mistake " was detected.

This story was buried by the MSM & the WHO, but it happened, & it is on the public record if you want to verify what I say, just google it.

Info Wars ! I know, & I am telling everyone.

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.